130308-48-4 Usage
Description
HOE 140, also known as Icatibant, is a synthetic oligopeptide that functions as a bradykinin receptor antagonist. It is a ten-membered peptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequence. HOE 140 is used in the treatment of acute attacks of hereditary angioedema in adult patients by blocking the effects of bradykinin, a potent vasodilator.
Uses
Used in Pharmaceutical Industry:
HOE 140 is used as a bradykinin receptor antagonist for the treatment of acute attacks of hereditary angioedema in adult patients. It works by blocking the effects of bradykinin, a potent vasodilator, which helps to alleviate the symptoms of the condition.
Used in Research Applications:
HOE 140 is also used in research settings to study the role of bradykinin in various physiological processes and disease states. As a bradykinin receptor antagonist, it can help researchers understand the mechanisms underlying conditions such as inflammation, pain, and vascular permeability.
Check Digit Verification of cas no
The CAS Registry Mumber 130308-48-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,3,0 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 130308-48:
(8*1)+(7*3)+(6*0)+(5*3)+(4*0)+(3*8)+(2*4)+(1*8)=84
84 % 10 = 4
So 130308-48-4 is a valid CAS Registry Number.
InChI:InChI=1/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38?,39-,40-,41-,42-,43?,44?,45?,46?/m0/s1
130308-48-4Relevant articles and documents
A METHOD FOR PRODUCTION OF HIGH PURITY ICATIBANT
-
Page/Page column 13-16, (2019/11/12)
The present invention provides a process for the manufacture of peptidomimetic drug icatibant with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a protected C-terminal fragment bound to a solid support and a protected N-terminal fragment, followed by cleavage from the support and resulting in a crude peptide of high purity, which is further purified to obtain pure icatibant in high yield. The invention further provides intermediates useful in the manufacturing process.
Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders
-
, (2008/06/13)
This invention relates to a method of treating a chronic fibrogenetic liver disorder and/or an acute liver disorder and/or complications associated therewith, comprising administering to a patient a therapeutically effective amount of a bradykinin antagonist. Particular complications associated with said liver disorders include portal hypertension, decompensation phenomena such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.
Cytolytic bradykinin antagonists
-
, (2008/06/13)
The present invention provides bradykinin antagonists effective to inhibit cancer cell growth. Also provided are methods of inhibiting lung cancer cell growth by administering a therapeutically effective amount of a dimerized bradykinin antagonist.